Combination Approach With Ritlecitinib and nbUVB Compared to Ritlecitinib Alone for Treating Vitiligo

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NICE ·

Keywords

ClinConnect Summary

This clinical trial is studying a new way to treat vitiligo, a condition that causes loss of skin color in patches and can affect a person’s quality of life. The study is comparing two treatments: one group will take a medicine called ritlecitinib by mouth every day, and the other group will take ritlecitinib plus receive a special light therapy called narrowband UVB twice a week. The goal is to see which treatment helps improve skin color more over one year.

People who have vitiligo, both active or stable types, and are between 6 and 74 years old may be eligible to join. The study will include people with different skin tones to make sure the treatments work well for everyone. Participants will visit the study center about eight times over 72 weeks for check-ups, skin tests, and blood samples. Women who could become pregnant will have regular pregnancy tests during the study. After the first year, all participants will continue taking ritlecitinib to further observe its effects. This trial is not yet recruiting but aims to find better ways to help people with vitiligo regain their skin color safely.

Gender

ALL

Eligibility criteria